Wang Huiling, Zhang Shenghong, Yu Qiao, Yang Guang, Guo Jing, Li Manying, Zeng Zhirong, He Yao, Chen Baili, Chen Minhu
From the Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China.
Medicine (Baltimore). 2016 Feb;95(5):e2703. doi: 10.1097/MD.0000000000002703.
Endoscopy is an important tool in screening and monitoring inflammatory bowel disease (IBD); however, it is invasive, costly, and associated with risks to the patients. Recently, circulating microRNAs (miRNAs) have emerged as promising noninvasive biomarkers. We proposed that the expression of serum microRNA223 (miR-223) could be a biomarker for IBD.Studies were conducted using serum samples from 100 patients with IBD (50 with Crohn's disease [CD] and 50 with ulcerative colitis [UC]) and 50 healthy controls. The expression of serum miR-223 was measured by quantitative reverse transcription-polymerase chain reaction. The clinical disease activity was assessed by measurement of the Crohn's disease activity index for CD and the Mayo score for UC. Endoscopies were performed and graded according to the simple endoscopic score for CD and the ulcerative colitis endoscopic index of severity scores for UC. Blood samples for the measurement of high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) were taken within 1 week before or after endoscopy.Serum miR-223 expression increased 2.2 times in patients with CD and 2.8 times in patients with UC compared with the control group. Most importantly, the level of serum miR-223 was correlated with several indicators of disease activity both in CD and UC. Serum miR-223 demonstrated a higher Spearman r value than ESR and hs-CRP in detecting the disease activity of patients with IBD.Serum miR-223 might be a promising biomarker for monitoring disease activity in IBD patients.
内镜检查是筛查和监测炎症性肠病（IBD）的重要工具；然而，它具有侵入性、成本高且与患者风险相关。最近，循环微小RNA（miRNA）已成为有前景的非侵入性生物标志物。我们提出血清微小RNA223（miR-223）的表达可能是IBD的生物标志物。
研究使用了100例IBD患者（50例克罗恩病[CD]和50例溃疡性结肠炎[UC]）和50例健康对照者的血清样本。通过定量逆转录-聚合酶链反应测量血清miR-223的表达。通过测量CD的克罗恩病活动指数和UC的梅奥评分评估临床疾病活动度。根据CD的简单内镜评分和UC的溃疡性结肠炎内镜严重程度指数进行内镜检查并分级。在内镜检查前或后1周内采集用于测量高敏C反应蛋白（hs-CRP）和红细胞沉降率（ESR）的血样。
与对照组相比，CD患者血清miR-223表达增加2.2倍，UC患者增加2.8倍。最重要的是，血清miR-223水平与CD和UC的几种疾病活动指标相关。在检测IBD患者的疾病活动度方面，血清miR-223的Spearman r值高于ESR和hs-CRP。血清miR-223可能是监测IBD患者疾病活动度的有前景的生物标志物。
